HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK)

HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) Produktliste

Attribut
Protein (5)
Produktbibliothek
Online (5)
Spezies
Human (5)
Etikett
His Tag & Avi Tag (2)His Tag (3)
Marker
Biotin-labeled (1)Unconjugated (2)AF488 Labeled (1)PE Labeled (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Vorbestellen/Bestellen
HOT HLD-H52E6	Human	HEK293	Unconjugated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified)	In den Warenkorb legen
HOT HLD-H52H7	Human	HEK293	Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein	In den Warenkorb legen
HOT HLD-H82E9	Human	HEK293	Biotinylated Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer, MALS verified)	In den Warenkorb legen
HOT HLD-HP2H6	Human	HEK293	PE-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Tetramer Protein	In den Warenkorb legen
HLD-HA2H4	Human	HEK293	Alexa Fluor™ 488-Labeled Human HLA-A*11:01&B2M&KRASG12D (VVVGADGVGK) Complex Protein (Monomer)	In den Warenkorb legen

Gesamtmenge5

Produktanfrage

HLA-A*1101 & B2M & KRASG12D (VVVGADGVGK) Molekülhintergrund

The Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and its signaling network represents a major target for therapeutic intervention. The Human HLA-A*1101 KRASG12D (VVVGADGVGK) complex protein is a complex of HLA-A*1101 of the MHC Class I, B2M, and VVVGADGVGK peptide of the KRASG12D.

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
VVN-001	VVN001; VVN-001	Phase 3 Clinical	VivaVision Biotech Inc	Dry Eye Syndromes; Xerophthalmia	Details
P-28-R	P-28- R	Phase 1 Clinical	Canimguide Therapeutics	Head and Neck Neoplasms	Details

Inverkehr gebrachte Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Frühestes Markenname	Frühestes Genehmigungsland	Früheste Indikation	Früheste Genehmigungsgesellschaft	Früheste Genehmigungsdatum	Indikationen	Klinische Studie
Odulimomab		Approved	Immunotech SAS	Antilfa	France	Graft vs Host Disease; Rejection of renal transplantation	null	1997-01-01	Rejection of renal transplantation; Graft vs Host Disease	Details